Literature DB >> 27250990

Prognostic Impact of the Initial Postoperative CA19-9 Level in Patients with Extrahepatic Bile Duct Cancer.

Yuichiro Kato1, Shinichiro Takahashi2, Naoto Gotohda2, Masaru Konishi2.   

Abstract

BACKGROUND: The aim of this study was to investigate the prognostic impact of the initial serum postoperative CA19-9 levels in patients with extrahepatic bile duct cancer.
METHODS: Data of a total of 143 patients of extrahepatic bile duct cancer with elevated preoperative serum CA19-9 levels (>37 U/ml) who underwent surgery with curative intent were reviewed retrospectively. The patients were divided into the "Normalization group" and "Non-normalization group" (initial postoperative serum CA19-9 ≤37 and >37 U/ml, respectively), and the clinicopathological factors and survival outcomes in these groups were comparatively analyzed.
RESULTS: The cumulative 5-year overall survival (OS) rate and median survival time (MST) were 39.2 % and 42.9 months, respectively, in the Normalization group and 17.9 % and 24.0 months, respectively, in the Non-normalization group (P < 0.001). Presence of jaundice, a poorer histological differentiation grade (G3-4), lymph node metastasis, and initial postoperative serum CA19-9 level (>37 U/ml) were significant independent predictors of a poor prognosis on multivariate analysis.
CONCLUSION: Non-normalization of the serum CA19-9 level in the initial postoperative phase is a strong predictor of a poor prognosis and is a useful marker to identify patients who would need additional treatments and stricter follow-up.

Entities:  

Keywords:  Bile duct cancer; CA19-9; Cholangiocarcinoma; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 27250990     DOI: 10.1007/s11605-016-3180-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  21 in total

1.  Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma.

Authors:  W R Jarnagin; Y Fong; R P DeMatteo; M Gonen; E C Burke; J Bodniewicz BS; M Youssef BA; D Klimstra; L H Blumgart
Journal:  Ann Surg       Date:  2001-10       Impact factor: 12.969

Review 2.  Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature.

Authors:  Murad Aljiffry; Alhawsawi Abdulelah; Mark Walsh; Kevork Peltekian; Ian Alwayn; Michele Molinari
Journal:  J Am Coll Surg       Date:  2008-10-31       Impact factor: 6.113

Review 3.  CA 19-9 as a marker for gastrointestinal cancers: a review.

Authors:  M J Duffy
Journal:  Ann Clin Biochem       Date:  1998-05       Impact factor: 2.057

4.  Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies.

Authors:  Yoshiaki Murakami; Kenichiro Uemura; Takeshi Sudo; Yasushi Hashimoto; Naru Kondo; Naoya Nakagawa; Takeshi Muto; Hayato Sasaki; Kazuhide Urabe; Taijiro Sueda
Journal:  J Gastrointest Surg       Date:  2013-08       Impact factor: 3.452

5.  Impact of ductal resection margin status on long-term survival in patients undergoing resection for extrahepatic cholangiocarcinoma.

Authors:  Toshifumi Wakai; Yoshio Shirai; Tetsuya Moroda; Naoyuki Yokoyama; Katsuyoshi Hatakeyama
Journal:  Cancer       Date:  2005-03-15       Impact factor: 6.860

Review 6.  Proximal biliary malignancy.

Authors:  Mohamed Akoad; Roger Jenkins
Journal:  Surg Clin North Am       Date:  2008-12       Impact factor: 2.741

7.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

8.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

9.  Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffman; L B Riley; A Rogatko; J A Ridge; B L Eisenberg
Journal:  Ann Surg Oncol       Date:  1997 Oct-Nov       Impact factor: 5.344

10.  The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.

Authors:  Timothy J Kinsella; Yuji Seo; Joseph Willis; Thomas A Stellato; Christopher T Siegel; Deborah Harpp; James K Willson; Joseph Gibbons; Juan R Sanabria; Jeffrey M Hardacre; James P Schulak
Journal:  Am J Clin Oncol       Date:  2008-10       Impact factor: 2.339

View more
  10 in total

1.  Serum carbohydrate antigen 125 is a significant prognostic marker in patients with unresectable advanced or recurrent gastric cancer.

Authors:  Tsutomu Namikawa; Yasuhiro Kawanishi; Kazune Fujisawa; Eri Munekage; Jun Iwabu; Masaya Munekage; Hiromichi Maeda; Hiroyuki Kitagawa; Michiya Kobayashi; Kazuhiro Hanazaki
Journal:  Surg Today       Date:  2017-10-17       Impact factor: 2.549

2.  Preoperative Cholangitis Affects Survival Outcome in Patients with Extrahepatic Bile Duct Cancer.

Authors:  Masayuki Akita; Tetsuo Ajiki; Taku Matsumoto; Kenta Shinozaki; Tadahiro Goto; Sadaki Asari; Hirochika Toyama; Masahiro Kido; Takumi Fukumoto; Yonson Ku
Journal:  J Gastrointest Surg       Date:  2017-03-13       Impact factor: 3.452

3.  Surgical outcomes and prognostic factors of distal common bile duct adenocarcinoma: chronological analysis in a single high-volume institutional experience.

Authors:  Ji Hye Jung; So Jeong Yoon; Ok Joo Lee; Sang Hyun Shin; In Woong Han; Jin Seok Heo
Journal:  BMC Surg       Date:  2022-07-04       Impact factor: 2.030

4.  Predictors of postoperative early recurrence of extrahepatic bile duct cancer.

Authors:  Masayuki Akita; Tetsuo Ajiki; Kimihiko Ueno; Daisuke Tsugawa; Yu Hashimoto; Motofumi Tanaka; Masahiro Kido; Hirochika Toyama; Takumi Fukumoto
Journal:  Surg Today       Date:  2019-09-23       Impact factor: 2.549

5.  CEA but not CA19-9 is an independent prognostic factor in patients undergoing resection of cholangiocarcinoma.

Authors:  Sven H Loosen; Christoph Roderburg; Katja L Kauertz; Alexander Koch; Mihael Vucur; Anne T Schneider; Marcel Binnebösel; Tom F Ulmer; Georg Lurje; Wenzel Schoening; Frank Tacke; Christian Trautwein; Thomas Longerich; Cornelis H Dejong; Ulf P Neumann; Tom Luedde
Journal:  Sci Rep       Date:  2017-12-05       Impact factor: 4.379

6.  Preoperative Bilirubin-Adjusted Carbohydrate Antigen 19-9 as a Prognostic Factor for Extrahepatic Cholangiocarcinoma Patients at a Single Center.

Authors:  Jiayi Li; Qiao Chen; Bao Jin; Yue Shi; Xiangan Wu; Haifeng Xu; Yongchang Zheng; Yingyi Wang; Shunda Du; Xin Lu; Yilei Mao; Xinting Sang
Journal:  Cancer Manag Res       Date:  2020-01-20       Impact factor: 3.989

7.  Serum carcinoembryonic antigen and carbohydrate antigen 19-9 as preoperative diagnostic biomarkers of extrahepatic bile duct cancer.

Authors:  Hyeong Seok Kim; Youngmin Han; Jae Seung Kang; Yoon Hyung Kang; Mirang Lee; Hee Ju Sohn; Hongbeom Kim; Wooil Kwon; Jin-Young Jang
Journal:  BJS Open       Date:  2021-11-09

8.  Prognostic Value of Carbohydrate Antigen 19-9 and the Surgical Margin in Extrahepatic Cholangiocarcinoma.

Authors:  Ryusei Yamamoto; Teiichi Sugiura; Ryo Ashida; Katsuhisa Ohgi; Mihoko Yamada; Shimpei Otsuka; Katsuhiko Uesaka
Journal:  Ann Gastroenterol Surg       Date:  2021-11-09

9.  High levels of serum glypican-1 indicate poor prognosis in pancreatic ductal adenocarcinoma.

Authors:  Cong-Ya Zhou; Yi-Ping Dong; Xiao Sun; Xin Sui; Hong Zhu; Ya-Qin Zhao; Yuan-Yuan Zhang; Clifford Mason; Qing Zhu; Su-Xia Han
Journal:  Cancer Med       Date:  2018-10-24       Impact factor: 4.452

10.  A Novel Approach to Assessing Differentiation Degree and Lymph Node Metastasis of Extrahepatic Cholangiocarcinoma: Prediction Using a Radiomics-Based Particle Swarm Optimization and Support Vector Machine Model.

Authors:  Xiaopeng Yao; Xinqiao Huang; Chunmei Yang; Anbin Hu; Guangjin Zhou; Jianbo Lei; Jian Shu
Journal:  JMIR Med Inform       Date:  2020-10-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.